We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck (NYSE: MRK), a leading U.S. drug manufacturer, has defied this industrywide trend in 2024. Merck's shares have seen a nearly 16% increase this year, outperforming the benchmark S&P 500 ...

The investment seeks to provide investors with an opportunity to invest in gold through the shares and be able to take delivery of physical gold in exchange for those shares. The Trust’s ...

My thesis at the time referred to Merck's strategic collaborations and pipeline developments, which would contribute to increasing the value of the stock in view of the company's expected ...

Merck recently acquired a small biotech. That biotech is making a technology to shut down certain cancer drugs before they harm patients. It could lead to doctors prescribing some of Merck's ...

Arne Dedert / picture alliance via Getty Images Merck beat earnings and revenue estimates on strong sales of its Keytruda cancer medicine and Gardasil HPV vaccine. The pharmaceutical giant ...

Significant growth in flagship products Keytruda and Gardasil helped drive results. Merck raised its full-year 2024 outlook, reflecting confidence in continued progress. The drugmaker reported non ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Today, we learn more about studying tumors at the ...

Merck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The company beat expectations with revenues of US$16b arriving 3.8% ahead of forecasts. Statutory ...

For instance, on April 5, Merck (NYSE: MRK) spent $208 million to acquire a business called Abceutics, which is developing a technology to nullify the effects of certain medicines that Merck is ...